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Abstract 
Stepped wedge and cluster randomised crossover trials are examples of cluster randomised 
designs conducted over multiple time periods that are being used with increasing frequency 
in health research. Recent systematic reviews of both of these designs indicate that the 
within-cluster correlation is typically taken account of in the analysis of data using a random 
intercept mixed model, implying a constant correlation between any two individuals in the 
same cluster no matter how far apart in time they are measured: within-period and 
between-period intra-cluster correlations are assumed to be identical. Recently proposed 
extensions allow the within- and between-period intra-cluster correlations to differ, 
although these methods require that all between-period intra-cluster correlations are 
identical, which may not be appropriate in all situations.  
Motivated by a proposed intensive care cluster randomised trial, we propose an alternative 
correlation structure for repeated cross-sectional multiple period cluster randomised trials 
in which the between-period intra-cluster correlation is allowed to decay depending on the 
distance between measurements. We present results for the variance of treatment effect 
estimators for varying amounts of decay, investigating the consequences of the variation in 
decay on sample size planning for stepped wedge, cluster crossover and multiple-period 
parallel-arm cluster randomised trials. We also investigate the impact of assuming constant 
between-period intra-cluster correlations instead of decaying between-period intra-cluster 
correlations. 
Our results indicate that in certain design configurations, including the one corresponding to 
the proposed trial, a correlation decay can have an important impact on variances of 
treatment effect estimators, and hence on sample size and power. An R Shiny app allows 
readers to interactively explore the impact of correlation decay. 
Keywords: exponential decay; intra-cluster correlation; cluster randomised trial; sample 
size; stepped wedge 
Abbreviations: BPICC: between-period intra-cluster correlation; CRT: cluster randomised 
trial; CRXO: cluster randomised cross over; ICU: intensive care unit; SW: stepped wedge; 
WPICC: within-period intra-cluster correlation
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1. Introduction 
Instead of randomly assigning subjects to treatment groups as in an individually-randomised 
trial, cluster randomised trials (CRTs) randomly assign clusters of subjects to treatment 
groups, where clusters may be schools, hospitals, geographical regions, or families, for 
example (1).  Given the clustered nature of the data, CRTs will generally require a larger 
total number of subjects to achieve the same power than required in a comparable 
individually randomised trial, but may have advantages in situations where individual 
randomisation is difficult (2). In this paper we consider multiple-period CRTs, where 
measurements are made on a cluster at multiple pre-defined time points throughout the 
trial. 
There are many types of multiple-period cluster-randomised designs, of which parallel-arm 
CRTs are the simplest. In parallel CRTs, clusters are randomly allocated to interventions 
(which we here label treatment or control) at trial commencement. Additionally, parallel 
CRTs may include one or more pre-intervention measures in each cluster: we refer to such 
designs as parallel with baseline CRTs. More complex, but with potential gains in power, are 
designs where clusters may switch between interventions over the course of the trial. 
Cluster randomised cross-over designs (CRXOs) randomise clusters to receive a sequence of 
interventions, rather than to receive a particular intervention. In CRXOs, clusters may switch 
back and forth between interventions one or more times over the course of the trial (3). 
Stepped wedge (SW) designs are a variant of CRXOs incorporating crossover in one direction 
only: in the standard SW design, in the first time period all clusters are in the control 
intervention, and by the last period all clusters are in the  treatment intervention (4, 5). All 
clusters switch from control to treatment at some point over the course of the trial, and will 
never revert to the control once switched to the treatment. In SWs, it is the time at which 
the switch from control to treatment occurs that is randomly allocated. More general 
cluster randomised multi-period designs have been discussed in (6). 
SWs have potential gains in power over similar parallel designs in certain circumstances, but 
are never as powerful as similar CRXOs when intra-cluster correlations are non-zero (4, 7). 
SWs are particularly useful in situations in which discontinuation of the intervention is 
difficult or some carry-over of treatment effect in one direction only (from treatment to 
control) is expected, in which case the CRXO design may not be applicable. The SW design is 
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also useful to assess the impact of a program destined to be rolled out across all clusters, or 
when the intervention is seen as desirable, in which case clusters may be more inclined to 
participate with the promise of eventually receiving the intervention during the course of 
the trial.  
It is now almost universally accepted that cluster randomised trials must acknowledge the 
effect of clustering at both the design and analysis stage. For single-period parallel CRTs, this 
acknowledgement is achieved through specification of the intra-cluster correlation, which 
represents the correlation between two observations in the same cluster. However, in a 
multiple-period cluster randomised trial, instead of a single intra-cluster correlation, the 
situation is more complicated: it may be appropriate for correlations between observations 
from the same cluster to be specified differently if they are in the same or different periods. 
We use the term “within-period intra-cluster correlation” (abbreviated as WPICC) to 
describe the correlation between two observations in the same cluster and in the same 
period; and the term “between-period intra-cluster correlation” (abbreviated as BPICC), to 
describe the correlation between two observations in the same cluster, but in different time 
periods. We note that other authors have used different terminology: (8), for example, use 
the term “intra-cluster correlation” for WPICC, and “inter-period correlation” for BPICC. For 
example, in CRXOs with two periods, the usual assumption is that the WPICC and BPICC are 
different, e.g. (8, 9). For CRTs with more than two periods, there may in fact be several 
BPICCs, corresponding to the correlation between observations taken in each pair of 
periods. However, the most-widely used model for the design of SW designs trials, the 
Hussey and Hughes random intercept mixed model for repeated cross-sectional data, 
implies the equality of within-period and between-period intra-cluster correlations (10, 11).  
The implausibility of the assumption that intracluster correlations do not depend on the 
time between observations has been discussed (e.g. (12-14)), and models proposed in (13) 
and (4) include separate within-period and between-period intra-cluster correlations, albeit 
with the assumption of invariance of BPICCs across time. In some situations, it may be more 
plausible to assume that the correlation between observations from the same cluster 
decays the further apart in time those observations were made. In this paper we consider a 
more general within-cluster correlation structure, in which the BPICC is allowed to vary 
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depending on the distance between measurement periods, implying that the BPICC is not 
constant within clusters.   
The specific example we will consider is a proposed CRT in Australian intensive care units 
(ICUs): data from the Australian and New Zealand Intensive Care Society Adult Patient 
Database, (15) indicates that an exponential decay within-cluster correlation structure, 
analogous to an autoregressive structure of order 1, which allows the correlations between 
observations to decay over time, provides a reasonable approximation to the data. Hence, 
in the planning of this trial the sensitivity of the required sample size to the usual 
assumption of a constant correlation within clusters (i.e. the Hussey and Hughes model) 
requires investigation. We explore the impact of an exponential decaying within-cluster 
correlation structure on the variance of treatment effects for repeated cross-sectional 
multiple-period parallel, CRXO and SW CRTs, and hence the impact on required sample sizes 
to detect given treatment effects.  Each subject is present in one time period only, which 
obviates the need for consideration of participant-level random effects from regression 
models. Alternative designs, in which subjects may contribute measurements in more than 
one period, are considered in the Discussion. 
In Section 2 we present general formulae for sample size calculations for multiple-period 
cross-sectional CRTs, first re-stating the main variance expression of Hussey and Hughes 
(10), and then extending it to more general within-cluster correlation structures. We apply 
these formulae to explore the consequences of the exponential decay within-cluster 
correlation structure on the variance of the estimated treatment effect in Section 3. In 
Section 4 we explore the consequences of the assumption of a constant BPICC structure 
(e.g. assuming the model of Hussey and Hughes (10), or that of  (13) and (4)) instead of an 
exponential decay BPICC structure on the variance of the estimated treatment effect. 
Results, extensions, and limitations are discussed in Section 5. Although our results and 
discussion are framed in terms of parameter estimates corresponding to the proposed ICU 
trial, we provide an R Shiny web app, (16), at https://monash-
biostat.shinyapps.io/NonUniformCorrelation to allow readers to explore the consequences 
of an exponential-decay within-cluster correlation structure for a range of design choices 
and parameter values. Users can also up-load their own design matrices. R code for local 
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implementation of the app is available in the online supplementary material, and at 
https://github.com/jkasza/NonUniformCorrelation.  
 
2. Sample size calculations for multiple-period CRTs 
2.1 Uniform correlation structure 
If  𝑌𝑖𝑡𝑘 denotes the outcome for subject 𝑘 = 1,… ,𝑚 in cluster 𝑖 = 1,… , 𝐾, during period 
𝑡 = 1,…𝑇, the usual Hussey and Hughes model, proposed by (10), is given by  
𝑌𝑖𝑡𝑘 = 𝜇 + 𝛽𝑡 + 𝑋𝑖𝑡𝜃 + 𝛼𝑖 + 𝑒𝑖𝑡𝑘, 𝛼𝑖 ∼ 𝑁(0, 𝜏
2), 𝑒𝑖𝑡𝑘 ∼ 𝑁(0, 𝜎𝑒
2).     (1) 
We assume that the number of subjects per cluster-period, 𝑚, is constant In this model 𝜇 is 
the overall mean outcome, 𝛽𝑡 is the fixed effect corresponding to period 𝑡, with 𝛽1 = 0 for 
identifiability;  𝑋𝑖𝑡 is the intervention variable, equal to 0 (1) if cluster 𝑖 is in the control 
condition (treatment)  at period 𝑡,  𝜃 is the intervention effect of interest, 𝛼𝑖 is the random 
effect of cluster 𝑖, and 𝑒𝑖𝑡𝑘 is the subject-level residual. As reported in recent systematic 
reviews, this model is the usual model assumed for cross-sectional stepped-wedge design 
sample size calculations (17-19). 
A key assumption of this model is that the correlation between observations from the same 
cluster is time-shift invariant: the correlation between any pair of observations in the same 
cluster remains constant no matter how far apart in time those two observations are  
𝑐𝑜𝑟𝑟(𝑌𝑖𝑡𝑘, 𝑌𝑖𝑡𝑙) = 𝑐𝑜𝑟𝑟(𝑌𝑖𝑡𝑘, 𝑌𝑖𝑠𝑙) =  
𝜏2
𝜏2+𝜎𝑒
2; an assumption which may not be plausible (12, 
13).  
2.2 Non-uniform correlation structure 
Here we extend the model in Equation (1) to allow a more general correlation structure 
between individuals within the same cluster. We assume the model  
𝑌𝑖𝑡𝑘 = 𝜇 + 𝛽𝑡 + 𝑋𝑖𝑡𝜃 + 𝐶𝑃𝑖𝑡 + 𝑒𝑖𝑡𝑘,    𝑪𝑷𝒊 ∼ 𝑁𝑇(0, 𝜎𝐶𝑃
2 𝑹), 𝑒𝑖𝑡𝑘 ∼ 𝑁(0, 𝜎𝑒
2),     (2) 
where terms in common with Equation (1) have the same interpretation as in that model, 
𝐶𝑃𝑖𝑡 is the cluster-period random effect for cluster 𝑖 in period 𝑡 with 𝑪𝑷𝒊 = (𝐶𝑃𝑖1, … , 𝐶𝑃𝑖𝑇)
′; 
we assume that the 𝐶𝑃𝑖𝑡 have common variance 𝜎𝐶𝑃
2  and 𝜎𝐶𝑃
2 𝑹 is the covariance matrix of 
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𝑪𝑷𝒊. We assume that subjects within a cluster observed in the same period have an 
exchangeable covariance structure 𝑐𝑜𝑣(𝑌𝑖𝑡𝑘, 𝑌𝑖𝑡𝑙) = 𝑣𝑎𝑟(𝐶𝑃𝑖𝑡) = 𝜎𝐶𝑃
2 , and that the 
covariance between any pair of subjects from the same cluster but different periods is given 
by 𝑐𝑜𝑣(𝑌𝑖𝑡𝑘, 𝑌𝑖𝑠𝑙) = 𝑐𝑜𝑣(𝐶𝑃𝑖𝑡, 𝐶𝑃𝑖𝑠).   We parameterise 𝑹 using 𝑅𝑡𝑠 = 𝑟𝑡𝑠, where 𝜎𝐶𝑃
2 𝑟𝑡𝑠 =
𝑐𝑜𝑣(𝐶𝑃𝑖𝑡 , 𝐶𝑃𝑖𝑠). The within-period intra-cluster correlation is 𝑐𝑜𝑟𝑟(𝑌𝑖𝑡𝑘, 𝑌𝑖𝑡𝑙) =
𝜎𝐶𝑃
2
𝜎𝐶𝑃
2 + 𝜎𝑒
2 ≔
𝜌0,  and the between-period intra-cluster correlation structure is given by 𝑐𝑜𝑟𝑟(𝑌𝑖𝑡𝑘, 𝑌𝑖𝑠𝑙) =
𝜎𝐶𝑃
2
𝜎𝐶𝑃
2 + 𝜎𝑒
2 𝑟𝑡𝑠 = 𝜌0𝑟𝑡𝑠 for 𝑡 ≠ 𝑠.  
A useful and quite general between-period intra-cluster correlation structure is the Toeplitz 
structure, 𝑟𝑡𝑠 = 𝑟|𝑡−𝑠|, with the restriction being that the choice of 𝑟𝑡𝑠 must ensure a 
positive definite 𝑹. An exponential decay structure (analogous to an autoregressive order 1 
correlation matrix) is returned if 𝑟𝑡𝑠 = 𝑟
|𝑡−𝑠|. A more general version of the autoregressive 
structure is obtained taking 
𝑹 = 𝑹(𝑟0, 𝑟) =  (
1 𝑟0𝑟 𝑟0𝑟
2 … 𝑟0𝑟
𝑇−1
𝑟0𝑟 1 𝑟0𝑟 … 𝑟0𝑟
𝑇−2
⋮ ⋮ ⋮ ⋮ ⋮
𝑟0𝑟
𝑇−1 𝑟0𝑟
𝑇−2 𝑟0𝑟
𝑇−3 … 1
) 
The Hussey and Hughes model is returned when 𝑹 = 𝑹(1,1). A model with constant 
between-period intra-cluster correlations, 𝑐𝑜𝑟𝑟(𝑌𝑖𝑡𝑘, 𝑌𝑖𝑡𝑙) ≠ 𝑐𝑜𝑟𝑟(𝑌𝑖𝑡𝑘, 𝑌𝑖𝑠𝑙) but 
𝑐𝑜𝑟𝑟(𝑌𝑖𝑡𝑘, 𝑌𝑖𝑠𝑙) =
𝜎𝐶𝑃
2
𝜎𝐶𝑃
2 + 𝜎𝑒
2 𝑟0, 𝑡 ≠ 𝑠, 𝑟0 a constant, analogous to that of Hooper et al (13) (and 
that of Girling and Hemming in (4)), is returned if 𝑹 = 𝑹(𝑟0, 1): we refer to this model as the 
Hooper/Girling model. This is equivalent to imposing an exchangeable correlation structure 
on {𝐶𝑃𝑖𝑡}. We note that the model we refer to as the Hooper/Girling model has the same 
within-cluster correlation structure as the model in Section 3.2 of (20), and is a special case 
of the model presented in (21). We will consider the autoregressive correlation matrix with 
𝑹 = 𝑹(1, 𝑟), the Hussey and Hughes, and the Hooper/Girling models in our comparative 
studies in Sections 3 and 4.  
2.3 Variance of the treatment effect estimator 
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Let ?̅?𝑖𝑡 = ∑
𝑌𝑖𝑡𝑘
𝑚
𝑚
𝑘=1  denote the mean outcome in cluster 𝑖 in period 𝑡. If ?̅?𝒊 = (?̅?𝑖1, … , ?̅?𝑖𝑇)′ is 
the vector of the period means for cluster 𝑖, then the variance-covariance matrix of ?̅?𝒊 in 
Equation (2) can be written as  
𝐶𝑜𝑣(?̅?𝒊) = 𝑽 =  (𝜎𝐶𝑃
2 +
𝜎𝑒
2
𝑚
)(𝜔𝑹 + (1 − 𝜔)𝑰𝑇) 
where 𝜔 = 𝜎𝐶𝑃
2 /(𝜎𝐶𝑃
2 +
𝜎𝑒
2
𝑚
) and 𝑰𝑇 is the 𝑇 × 𝑇 identity matrix. If 𝑿𝒊 = (𝑋𝑖1, … , 𝑋𝑖𝑇)′ is the 
column vector of length 𝑇 of treatment indicators for cluster 𝑖, then we show in Appendix A 
that 
𝑣𝑎𝑟(𝜃) =  
(
 
 
 
∑𝑿𝒊
′𝑽−1𝑿𝒊
𝐾
𝑖=1
− 
1
𝐾
(∑ 𝑋𝑖1
𝐾
𝑖=1
, … ,∑ 𝑋𝑖𝑇
𝐾
𝑖=1
 ) 𝑽−1
(
 
 
∑ 𝑋𝑖1
𝐾
𝑖=1
⋮
∑ 𝑋𝑖𝑇
𝐾
𝑖=1 )
 
 
)
 
 
 
−1
, 
where the vector (∑ 𝑋𝑖1
𝐾
𝑖=1 , … , ∑ 𝑋𝑖𝑇
𝐾
𝑖=1  ) is the number of treated clusters in periods 1 to 𝑇. 
Here we assume that 𝐶𝑜𝑣(?̅?𝒊) is constant across clusters. In models where the variance 
matrices differ across clusters this expression will not hold: for example, this would be the 
case when clusters are of different sizes. 
When decay is exponential, with 𝑹 = 𝑹(1, 𝑟), 𝑟 ≠ 1, or the more complex 𝑹(𝑟0, 𝑟), 𝑟 ≠ 1, 
simple closed form expressions for the variance of the treatment effect are difficult to 
obtain, requiring the inversion of tridiagonal matrices with non-standard forms, hence in 
our comparative studies we numerically invert the variance matrix 𝑉 using the standard 
matrix inversion command “solve” in R. For the Hussey and Hughes (𝑹 = 𝑹(1, 1)) and 
Hooper/Girling models (𝑹 = 𝑹(𝑟0, 1)), closed-form expressions for 𝑣𝑎𝑟(𝜃) are available, 
e.g. (6). 
 
3. Consequences of a more general within-cluster covariance matrix structure 
3.1 A proposed intensive care trial 
As part of the planning for a potential four period CRXO trial of the effect of overnight 
placement of earplugs in intensive care patients on hospital length of stay,  data from four 
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six-month periods over 2012 and 2013 from 33 ICUs contributing to the Australian and New 
Zealand Intensive Care Society’s Adult Patient Database (15) was used to investigate the 
empirical correlation structure over these 4 periods.  Ethical review was not required. There 
were on average 700 patients per ICU per 6 month period. We fit linear mixed models to the 
logarithm of length of stay with exponential decay and Toeplitz correlation structures for 
the cluster-period random effects, using the hpmixed and mixed procedures in SAS, 
respectively, which allow for the inclusion of correlation structures in the random 
statement. We found that an exponential decay correlation structure provided a reasonable 
approximation to the data, with 𝜎𝐶𝑃
2 = 0.039, 𝜎𝑒
2 = 1.09 (implying that 𝜌0 = 0.035), and 
 ?̂? = 0.95, implying a 5% decay per period in the correlation between observations from the 
same intensive care unit.   
3.2 Design of the comparative study 
We first consider the impact of assuming an exponential decay within-cluster correlation 
structure on the variance, power, and design effects of various types of standard multi-
period CRTs, where the design effect is the ratio of the variance of the treatment effect for 
the CRT relative to the variance for an individually-randomised trial of the same size. To 
provide an example of specific designs, we compare the choices of the four-period trial 
designs shown in Figure 1 and the eight-period designs in Appendix Figure 1, calculating the 
variance of the estimator of the treatment effect and associated quantities by  fixing the 
total variance at unity (i.e. 𝜎𝐶𝑃
2 +  𝜎𝑒
2 = 1 so that the within-period intra-cluster correlation 
𝜌0 = 𝜎𝐶𝑃
2 ), and assuming the within-cluster covariance matrix 𝑅 = 𝑹(1, 𝑟): i.e. 𝑹 has (𝑡, 𝑠) 
element 𝑟𝑡𝑠 = 𝑟
|𝑡−𝑠|.  Since the total variance has been fixed at 1, results are obtained by 
varying the WPICC 𝜎𝐶𝑃
2 = 𝜌0, and the parameter associated with the BPICC, 𝑟. For easier 
interpretation, we define decay as 𝑑 = 1 − 𝑟: 𝑑 = 0 thus implies no decay in correlation 
over time, while 𝑑 = 1 implies a total decay in correlation over time with independence 
between observations from the same cluster in different periods. Larger values of the decay, 
d, are not realistic and hence our attention focusses on values less than 0.5. 
In presenting the results of this comparative study we focus on the scenario corresponding 
to the proposed intensive care trial, assuming 500 patients per ICU (allowing for a reduction 
from 700 per period in the considered dataset due to loss to follow up, patient refusal, etc.) 
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for each of four (or eight) periods with 𝜌0 = 0.035. We also present results for designs with 
50 subjects per cluster per period.   
The four-period stepped wedge design consists of 3 randomised sequences, while the four-
period parallel, parallel with baseline and CRXO designs consist of 4 sequences each. 
Similarly, the eight-period stepped wedge design consists of 7 sequences, while the eight-
period parallel, parallel with baseline and CRXO designs consist of 8 sequences each. While 
designs in practice may assign more than one cluster to each treatment sequence, in our 
comparative study we assume that there is one cluster per sequence: thus, to allow 
comparability of the variance of the treatment effect across these designs with differing 
numbers of clusters (3 for the four-period SW versus 4 for all other four-period designs), we 
scale the variance associated with the SW design by 
𝐾
𝐾+1
=
#clusters
#clusters+ 1
  to ensure 
comparability.  
We calculate each of the following: the variance of the treatment effect; the design effects; 
and the power of each of the designs to detect specific user-specified effect sizes. Scaling 
the variance ensures that these subsequent quantities are comparable between the designs 
with differing numbers of clusters. Interested readers can interactively explore the impact of 
alternative design configurations through our R Shiny web app. Although we do not include 
the results in the main paper, the R Shiny app also allows each of these quantities to be 
calculated for the Hooper/Girling model with 𝑹(𝑟0 = 1 − 𝛼, 1) for some user-specified 
value of 𝛼 ∈ [0,1], analogous to the decay parameter 𝑑 associated with the exponential 
decay model. 
3.3 Results of the comparative study and consequences for the proposed ICU trial 
Figure 2 presents the variance for four-period designs (top row) and for eight-period designs 
(bottom row), for design parameters that align with those of the ICU trial (𝜌0 = 0.035 and 
50 subjects in each cluster period (left column) and 500 subjects in each cluster-period (right 
column), for values of the decay up to 0.5). When the decay = 0 (returning the standard 
Hussey and Hughes model) the BPICC is maximised (and equal to the WPICC), and the 
amount of information available from within-cluster comparisons is maximised. In this case, 
it is known that the CRXO design is optimal, e.g. (4), which is reflected in Figure 2. As the 
decay term increases, the BPICC reduces, and Figure 2 indicates that the variance associated 
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with the CRXO, parallel with baseline and SW designs increase, while the variance 
associated with the parallel CRT design reduces. As an aside, we note that for small values of 
the decay, there is often a large reduction in the variance of the treatment effect when a 
baseline measurement is added to the parallel design.  
Comparing the variance plots for four and eight periods indicates that the relationship 
between the variance and the decay parameter is consistent across the different designs as 
the number of periods increases. For the parallel design, as the decay increases, and 
dependence between observations in different periods decreases, the variance also 
decreases, while an increasing relationship between the decay and the variance is observed 
for the CRXO design. For the SW and parallel with baseline designs, although the variance 
initially increases with increasing decay, for each design the variance peaks at a particular 
value of the decay before decreasing again (for the SW design this value of the decay is 
outside of the displayed range).  
Figure 3 displays the ‘design effect’ associated with each of the designs, for each of the 
considered design configurations: the design effect re-scales the variances of Figure 2 to be 
relative to that of an individually-randomised trial of the same size. Figure 4 displays the 
power to detect an effect size of 0.2 associated with each design, and this is as expected 
given the variances in the left column.   
For small values of the intra-cluster correlation (𝜌0 less than about 0.01), for particular 
design configurations (e.g. 50 subjects per cluster-period with 4 periods for particular values 
of the decay, see Appendix Figure 2) the parallel CRT estimates the treatment effect more 
precisely than the SW-CRT does: this is known to occur in the exchangeable setting (4).  
 
4. Consequences of specifying a simpler between-period intra-cluster correlation structure 
4.1 Motivation 
The proposed ICU trial is unusual in that an extensive dataset is available at the planning 
stages of the trial for the estimation of WPICCs and BPICCs. In situations where data for the 
estimation of within-cluster correlation structure at the planning stages of a trial is limited, 
assessing the fit of an exponential decay structure to the data may be impossible and 
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researchers may prefer to assume a simpler within-cluster correlation structure. In this 
section we compare the variance of the treatment effect estimator under the exponential 
decay within-cluster structure with 𝑹 = 𝑹(1, 𝑟) (i.e. 𝑐𝑜𝑟𝑟(𝑌𝑖𝑡𝑘, 𝑌𝑖𝑠𝑙) = 𝜌0𝑟
|𝑡−𝑠|) to that 
obtained assuming the Hussey and Hughes model, with 𝑹 = 𝑹(1,1) (i.e. 𝑐𝑜𝑟𝑟(𝑌𝑖𝑡𝑘, 𝑌𝑖𝑡𝑙) =
𝑐𝑜𝑟𝑟(𝑌𝑖𝑡𝑘, 𝑌𝑖𝑠𝑙) = 𝜌0), and to that obtained assuming the Hooper/Girling model with 𝑹 =
𝑹(1 − 𝛼, 1) (i.e. 𝑐𝑜𝑟𝑟(𝑌𝑖𝑡𝑘, 𝑌𝑖𝑡𝑙) = 𝜌0 and 𝑐𝑜𝑟𝑟(𝑌𝑖𝑡𝑘, 𝑌𝑖𝑠𝑙) = 𝜌0(1 − 𝛼), ∀𝑡 ≠ 𝑠 for some 
constant 𝛼 ∈ [0,1]). Recalling that 𝑑 = 1 − 𝑟, the three models are equivalent when 𝑑 =
𝛼 = 0. We refer to the variance of the treatment effect estimator obtained using the 
Hussey and Hughes model as 𝑣𝑎𝑟𝐻𝐻(𝜃), that obtained given an exponential decay model 
with decay 𝑑 as 𝑣𝑎𝑟𝑑
𝐸(𝜃), and that obtained given a Hooper/Girling model with parameter 
𝛼 as 𝑣𝑎𝑟𝛼
𝐻𝐺(𝜃).  
We follow the design of the comparative study outlined in Section 3.2, calculating 𝑣𝑎𝑟𝑑
𝐸(𝜃) 
for a range of decay parameter values 𝑑, and in the first instance dividing this quantity by 
𝑣𝑎𝑟𝐻𝐻(𝜃). To compare the exponential decay model to the Hooper/Girling model, for each 
value of 𝑑 ∈ [0, 0.5] and each 𝛼 ∈ [0, 0.5] we calculate 𝑣𝑎𝑟𝑑
𝐸(𝜃)/𝑣𝑎𝑟𝛼
𝐻𝐺(𝜃). We display the 
results of the exponential and Hooper/Girling comparisons as a contour plot: 𝑑 on the x-
axis, 𝛼 on the y-axis, with the magnitude of the relative variance displayed using shades of 
grey. 
4.2 Comparison to the Hussey and Hughes model 
Figure 5 displays the relative variance of the treatment effect associated with the 
exponential decay model to that of the Hussey and Hughes model, for each of the four 
considered design types, for four-period designs (top row); eight-period designs (bottom 
row); designs with 50 subjects per cluster-period (left column); and designs with 500 
subjects per cluster-period (right column). Figure 5 indicates that the variance of the 
treatment effect will be underestimated by the Hussey and Hughes model when there is an 
exponential decay structure for the SW and CRXO designs, while the variance is 
overestimated for the parallel design. For the parallel with baseline design, for most design 
configurations the Hussey and Hughes model will underestimate the variance, although 
there do exist design configurations in which the Hussey and Hughes model will 
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overestimate the variance: this occurs for values of the decay parameter that are larger than 
usually seen in practice. 
Figure 5 indicates that for most design configurations, the impact of assuming the Hussey 
and Hughes model on the treatment effect variance is exacerbated as the number of 
periods increases and as the number of subjects per cluster-period increases. An exception 
occurs with the parallel with baseline design, which for certain values of the decay has a 
lower relative variance for a larger number of periods and subjects per cluster-period.  
The upper right panel of Figure 5 shows that for the proposed intensive care trial, with 5% 
decay, 𝜌0 = 0.035 and 500 patients per cluster per period, for a 4-period SW trial, the 
variance of the exponential decay model is around 1.8 times higher than that of the 
exchangeable model. For the eight-period SW trial, 𝑣𝑎𝑟𝑑
𝐸(𝜃) ≈ 2.8 × 𝑣𝑎𝑟𝐻𝐻(𝜃). Hence, 
were an exchangeable model assumed in the planning stages of this trial, the sample size 
required to detect the effect size of interest would be drastically underestimated. Similar 
results hold for CRXO and parallel-with-baseline designs, while for the parallel design the 
assumption of a constant correlation results in an increased variance relative to the 
exponential decay model.  
4.3 Comparison to the Hooper/Girling model 
Figure 6 displays the results of comparing 𝑣𝑎𝑟𝑑
𝐸(𝜃), 𝑑 ∈ [0,0.5] to 𝑣𝑎𝑟𝛼
𝐻𝐺(𝜃), 𝛼 ∈ [0,0.5], 
for designs with four periods (top row) and eight periods (bottom row). Contours are used 
to display ranges of values of 𝑣𝑎𝑟𝑑
𝐸(𝜃)/𝑣𝑎𝑟𝛼
𝐻𝐺(𝜃): values greater than one indicate that  
𝑣𝑎𝑟𝑑
𝐸(𝜃)is greater than 𝑣𝑎𝑟𝛼
𝐻𝐺(𝜃). On each plot 𝑑 = 𝛼 is marked with a line.  
By examining the edge between the 0.75-1 and 1-2 regions of the contour plots, marked 
with a bold line on all plots, values of the Hooper-Girling 𝛼 parameter that result in the 
same variance as an exponential decay model with a given decay parameter 𝑑 = 1 − 𝑟 can 
be obtained. The top-left plot of Figure 6 indicates that for the SW model on 4 periods, for 
values of 𝑑 less than about 0.3, 𝑣𝑎𝑟𝑑
𝐸(𝜃) ≈ 𝑣𝑎𝑟𝛼
𝐻𝐺(𝜃) for 𝑑 = 𝛼. For this scenario and 
these values of the decay, assumption of either model with 𝑑 = 𝛼 will result in similar 
required sample sizes. However, this is a special case: the bottom left hand plot in Figure 6 
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indicates that for the Hooper/Girling model to return the same variance as the exponential 
decay model for a SW design on 8 periods, 𝛼 > 𝑑: e.g. when 𝑑 = 0.05, 𝛼 ≈ 0.088. 
Figure 6 indicates that in general, the relationship between 𝑑 and 𝛼 required to return 
similar values for the treatment effect variances given these two models may be complex: 
depending on the design and number of periods, simply assuming that 𝑑 = 𝛼 could lead to 
an over- or under-estimation of the treatment effect variance, with a corresponding over- or 
under-estimation of required sample size. Some general relationships hold: for the CRXO 
and parallel designs, for 𝛼 = 𝑑, 𝑣𝑎𝑟𝑑
𝐸(𝜃) ≤ 𝑣𝑎𝑟𝛼
𝐻𝐺(𝜃). However, Figure 6 indicates that for 
the CRXO design, 𝑣𝑎𝑟𝑑
𝐸(𝜃) = 𝑣𝑎𝑟𝛼
𝐻𝐺(𝜃) implies that 𝛼 ≤ 𝑑, while for the parallel 
design, 𝑣𝑎𝑟𝑑
𝐸(𝜃) = 𝑣𝑎𝑟𝛼
𝐻𝐺(𝜃) implies that 𝛼 ≥ 𝑑. 
In Appendix Figure 3 we display extended versions of the plots of Figure 6, with 500 subjects 
per cluster-period, extending the range of 𝑑 and 𝛼 to [0,1]; Appendix Figure 4 displays 
analogous plots for designs with 50 subjects per cluster-period. Appendix Figure 3 indicates 
that for the parallel and CRXO designs, for all values of 𝑑 there exists a value of 𝛼 such that 
𝑣𝑎𝑟𝑑
𝐸(𝜃) = 𝑣𝑎𝑟𝛼
𝐻𝐺(𝜃). That this holds for other parameter choices in these designs can be 
seen by interrogating the R Shiny app. However, for the SW and parallel with baseline 
designs, there exist values of 𝑑 such that no value of 𝛼 exists such that 𝑣𝑎𝑟𝑑
𝐸(𝜃) =
𝑣𝑎𝑟𝛼
𝐻𝐺(𝜃). For example, for the SW design on 4 periods with 500 subjects per cluster in 
each period, for 𝑑 ∈ (0.78, 0.96), there does not exist an 𝛼 such that 𝑣𝑎𝑟𝑑
𝐸(𝜃) =
𝑣𝑎𝑟𝛼
𝐻𝐺(𝜃). For the SW design on 8 periods with 500 subjects per cluster per period, there 
exists no corresponding 𝛼 for 𝑑 ∈ (0.43, 0.89). For the stepped wedge and parallel with 
baseline designs, there is not a 1-1 correspondence between the Hooper/Girling model and 
the exponential decay model.  
Figure 6 indicates that there can be large differences between 𝑣𝑎𝑟𝑑
𝐸(𝜃) and 𝑣𝑎𝑟𝛼
𝐻𝐺(𝜃): 
should the within-cluster correlation structure be misspecified, it is possible to grossly over- 
or under-estimate the variance of the treatment effect, although Appendix Figure 4 
indicates that the over-estimation will not be as extreme for a smaller number of subjects 
per cluster-period. Hence, at the design stage of any trial, researchers should investigate the 
sensitivity of the required sample size and/or power of their study to misspecification of the 
within-cluster correlation structure.  
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5. Discussion 
Although the usual assumption in planning multiple-period CRTs is that the correlation 
between observations does not depend on the time between these observations, i.e. the 
assumption of the correlation structure of Hussey and Hughes (10), this assumption may be 
invalid. In many situations it would be more reasonable to assume that the correlation 
between observations on subjects from the same cluster will decrease the further apart in 
time these observations are obtained. This is well appreciated for individual subject 
longitudinal data, e.g. (22). We have shown that for designs with a treatment switch, even a 
decay in between-period intra-cluster correlation as small as 5% per period may appreciably 
inflate the required sample size relative to that required under an assumption of equality of 
within-period and between-period intra-cluster correlations, and discussed these results in 
the context of a proposed cluster randomised trial in the intensive care setting. For this 
proposed SW trial, the impact of a decay in the between-period intra-cluster correlation of 
5% per period results in a sample size almost double that required when no decay (i.e. the 
Hussey and Hughes model) is assumed. The implication is that cluster randomised trials that 
incorporate treatment switching but do not account for this decay, and instead assume that 
an equal amount of information is available from each within-cluster between-period 
comparison, may be dangerously underpowered to detect stated effect sizes, as has been 
observed in (13).  
For parallel cluster multi-period trials, as the decay increases (i.e. as between-period intra-
cluster correlation decreases), precision increases: thus, parallel designs that assume no 
decay in the between-period intracluster correlation may be overpowered to detect the 
stated effect size and thus may suffer from a lack of efficiency. For the SW and CRXO 
designs, precision is greatest when there is no decay in the inter-period correlations (𝑟 = 1 
or the decay = 0). The greater the correlation between observations from the same cluster 
at different time points, the greater the gains of the within-cluster comparisons that the SW 
and CRXO designs entail. This has been described in the context of cluster-randomised cross 
over designs in (3). As the decay increases, the correlation between observations from the 
same cluster but in different periods decreases. For designs such as the SW and CRXO, 
which capitalise on comparisons within clusters, this leads to an increase in the variance of 
the treatment effect, while for the parallel design, which does not incorporate any within-
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cluster comparisons, independence between observations within the same cluster in 
different periods (which occurs when the decay = 1) is optimal. 
To date, sample size calculations for stepped wedge designs taking into account that within 
and between correlations differ have assumed that between-period intra-cluster 
correlations are constant, as in the Hooper/Girling model we considered in Section 4, 
described in (13), for example. In some situations such an assumption will likely be more 
appropriate than the assumption of an exponential decay structure the cluster has 
completely re-organised itself in the interval between consecutive cross-sections. As an 
example, suppose clusters are schools in which the same year group is assessed over a 
number of years. This year-group is a completely different group of children each year, so 
the correlation between pairs of observations from different years may remain constant 
rather than decaying as the number of years between groups increases. However, we 
encourage researchers to assess the sensitivity of their power and sample size to any 
assumption regarding the within-cluster correlation structure. Although it may be 
convenient for investigators to assume the Hooper/Girling model at the trial design stage, 
perhaps adopting a conservative value for the between-period intra-cluster correlations, we 
have demonstrated that, although there exist choices of constant between-period intra-
cluster correlations (the Hooper/Girling 𝛼 parameter) corresponding to many values of 
exponential decay parameters, such choices are not always available for the stepped wedge 
and parallel with baseline designs. Moreover, approximating an exponential-decay 
correlation structure with a Hooper/Girling model with 𝑑 = 𝛼 (i.e. assuming that the lag 1 
decay persists for all larger lags) may over- or under-estimate the variance of the treatment 
effect, possibly dramatically so. For SW designs, whether the variance is over- or under-
estimated by a given constant between-period intra-cluster correlation approximation 
depends on the number of periods, the number of subjects per cluster-period, and the 
within-period intra cluster correlation, 𝜌0. 
In order to calculate the required sample size for a given trial assuming an exponential-
decay between-period intra-cluster correlation structure, an estimate of the decay 
parameter is required: such an estimate may be difficult to obtain. More generally, the 
estimate of the parameter 𝜌0 (the within-period intracluster correlation) may be based on 
data from multiple periods, and thus may itself incorporate a decay in between-period intra-
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cluster correlation over time: precisely what the impact of such model misspecification is on 
the estimated decay parameters and on 𝜌0 remains unclear. We expect that conducting a 
sample size calculation on the basis of a value of 𝜌0 estimated from a misspecified Hussey 
and Hughes model, which estimates 𝜌0 over all time periods combined rather than within a 
single period, then using a Hussey and Hughes model to calculate sample size, will lead to an 
under-estimation of the true variance of the treatment effect. However, if values of the 
BPICC and WPICC are obtained from a missppecified Hooper/Girling model, it seems that 
the estimate of the WPICC will incorporate some additional decay over time, and the impact 
of assuming a Hooper/Girling model on estimated sample size may be lessened. Further 
research is required to quantify the impact of model misspecification at the trial design 
stage. As has been pointed out in (13) for the case of a constant between-period intra-
cluster correlation, authors of reports of multi-period CRTs should be encouraged to report 
estimates of within-period and between-period intra-cluster correlations to help guide the 
choice of such parameters. Although there have been many studies that present within-
period intra-cluster correlations for each period of a study separately, for example (23,24), 
we would recommend that authors also report between-period intra-cluster correlations, as 
recommended in (25), for example.  
In order for a power calculation to be relevant, it is necessary that the analysis strategy 
applied at the completion of any trial match that used in the sample size calculation, at least 
approximately.  To that end, the Hussey and Hughes model and the Hooper/Girling model 
have an advantage over the exponential decay model. Many statisticians will be familiar 
with techniques for fitting these models, however, the exponential decay model we have 
considered here is not as widely used. For the proposed ICU trial, we applied the hpmixed 
procedure in SAS, incorporating the exponential decay structure on the cluster-level random 
effects by including the following statement: random period / sub = cluster 
type = AR(1).  Readers may be interested to note that we applied the hpmixed 
procedure due to large cluster sizes requiring extensive computational time with the mixed 
procedure.  Parameters for datasets with smaller cluster sizes may be estimated using the 
conventional mixed procedure. 
In this paper we have discussed exponential decay structures in the context of repeated 
cross-sectional multiple-period CRTs: that is, we have supposed that subjects are each 
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included in a single cluster-period. Multiple measurements for each subject, as occur in so-
called closed or open cohort designs, (5), could be accommodated through the inclusion of a 
subject-level random effect, as in (13). The model proposed in (13) implies that the 
correlation between two measurements on the same individual does not depend on the 
time between the measurements: a similar extension to the one we have here proposed for 
the cluster level random effects would be possible at the subject level. However, there are 
likely to be difficulties in the estimation of the parameters of such a model with exponential 
decay at both cluster and individual levels. Further extensions, such as allowing variances to 
increase over time, for correlations to change within a period, or for correlations to depend 
on some function of time, are possible, but given the potential difficulties in specifying these 
at the design stage, we have not explored these here. 
In this paper we have focussed on models for normally distributed outcomes: although we 
expect the conclusions drawn regarding the implications of an exponential decay intra-
cluster correlation structure on power to be similar for binary outcomes, particularly in the 
case of large clusters, further work is required. Both subject-specific and population-
averaged models could be investigated: for population-averaged models this could involve 
extending the working correlation matrix structures for the pre- post-test CRTs examined in 
(26) to the multiple-period scenario. 
The models we have assumed here include a categorical term for period, with a constant 
effect of period across clusters, that the effect of periods is constant across clusters, and a 
constant effect of treatment across clusters and periods. Other authors have considered 
more complex models e.g. (20, 27, 28). For studies conducted over a large number of 
periods, it may be advantageous to model time using continuous terms; however, specifying 
the correct functional form for time will likely be difficult at the design stage of a study. 
In conclusion, in this paper we have illustrated settings where exponentially decaying 
correlation can have a substantial impact on the variance of treatment effect estimators 
associated with multiple period cluster randomised trials, and hence on sample size and 
power calculations.  This is particularly important for stepped wedge trials which incorrectly 
assume constant between-period intra-cluster correlations. We have described, and have 
made available in an RShiny app (https://monash-
biostat.shinyapps.io/NonUniformCorrelation/), a facility for carrying out comparative 
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studies of the nature described in this paper: for their particular multiple-period cluster 
randomised trial, users can investigate the impact of an exponential decay structure on the 
required sample size and power of their study, either by setting the values of design 
parameters or up-loading their own design matrix. 
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Figure legends 
Figure 1. Design matrices corresponding to the 4-period designs considered in the 
comparative study. 
Figure 2: Variance of the treatment effect estimator for multiple-period cluster designs for 
50 subjects per cluster-period (left column), and 500 subjects per cluster-period (right 
column). Variances are shown for the four-period stepped wedge, parallel cluster, parallel 
cluster with baseline, and cluster cross over designs given in Figure 1 (top row), and for 
eight-period designs in Appendix Figure 1 (bottom row), for varying values of the 
exponential decay correlation structure decay parameter. For all designs, the within-period 
intra-cluster correlation 𝜌0 = 0.035. For the parallel, parallel with baseline and cross-over 
designs, results are scaled to allow comparison with the stepped wedge results. Note that 
the vertical scales for the 4-period and 8-period designs differ. 
Figure 3. Design effects for the treatment effect estimator for multiple-period cluster 
designs for 50 subjects per cluster-period (left column), and 500 subjects per cluster-period 
(right column). Design effects are shown for the four-period stepped wedge, parallel cluster, 
parallel cluster with baseline, and cluster cross over designs given in Figure 1 (top row), and 
for eight-period designs in Appendix Figure 1 (bottom row), for varying values of the 
exponential decay correlation structure decay parameter. For all designs, the within-period 
intra-cluster correlation 𝜌0 = 0.035. For the parallel, parallel with baseline and cross-over 
designs, results are scaled to allow comparison with the stepped wedge results. Note that 
the vertical scales for all plots differ. 
Figure 4. Power of the multiple-period cluster designs for 50 subjects per cluster-period (left 
column), and 500 subjects per cluster-period (right column) to detect an effect size of 0.2. 
The thin line at the top of each plot denotes power = 1. Power is shown for the four-period 
stepped wedge, parallel cluster, parallel cluster with baseline, and cluster cross over designs 
given in Figure 1 (top row), and for eight-period designs in Appendix Figure 1 (bottom row), 
for varying values of the exponential decay correlation structure decay parameter. For all 
designs, the within-period intra-cluster correlation 𝜌0 = 0.035. For the parallel, parallel with 
baseline and cross-over designs, results are scaled to allow comparison with the stepped 
wedge results. Note that the vertical scales for all plots differ. 
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Figure 5. Variance of the treatment effect estimator obtained given an exponential decay 
model (with varying values of decay) relative to the variance of the treatment obtained for 
the Hussey and Hughes model. The y-axis of each plot is on the log (base 10) scale. The top 
row gives results for the four-period designs given in Figure 1; the bottom row for eight-
period designs in Appendix Figure 1. The left column displays results for 50 subjects per 
cluster per period, and the right column for 500 subjects per cluster per period. For all 
designs, the within-period intra-cluster correlation 𝜌0 = 0.035. For the parallel, parallel with 
baseline and cross-over designs, results are scaled to allow comparison with the stepped 
wedge results. 
Figure 6. Contour plots of the variance of the treatment effect estimator obtained given an 
exponential decay model relative to that given the Hooper/Girling model, for varying values 
of the exponential decay model decay parameter and the Hooper/Girling 𝛼 parameter. The 
top row displays results for the four-period designs in Figure 1, and the bottom row displays 
results for the eight-period designs in Appendix Figure 1. For all designs, the within-period 
intra-cluster correlation 𝜌0 = 0.035, with 500 subjects per cluster per period. The line of 
equality between the two parameters is marked with a thin line, and equality of the 
variances is marked with thick lines on each plot. 
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